Acadia Pharmaceuticals | ACAD - Interest Expense On Debt


Acadia Pharmaceuticals reported $0 in Interest Expense on Debt for its fiscal quarter ending in September of 2024.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
ALKERMES USD 20.89M 8.62M Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Bristol-Myers Squibb USD 411M 21M Mar/2026
Cara Therapeutics -89.64M 128.67M Dec/2025
Corcept Therapeutics USD 814.88M 809.46M Mar/2026
Cytokinetics USD 33.34M 3M Mar/2026
Eisai JPY 1.55B 117M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Incyte USD 569K 13K Mar/2026
J&J USD 43M 25M Mar/2026
Moderna USD 11.49B 36B Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pfizer USD 671M 40M Mar/2026
Prothena USD 349.89M 347.27M Mar/2026
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025